Exelixis, Inc. (NASDAQ:EXEL) Director Stelios Papadopoulos sold 200,000 shares of Exelixis stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $27.68, for a total transaction of $5,536,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Stelios Papadopoulos also recently made the following trade(s):
- On Monday, September 18th, Stelios Papadopoulos sold 72,210 shares of Exelixis stock. The shares were sold at an average price of $27.76, for a total transaction of $2,004,549.60.
Shares of Exelixis, Inc. (NASDAQ:EXEL) traded up 1.25% during mid-day trading on Wednesday, reaching $28.27. 3,128,940 shares of the company’s stock were exchanged. The firm has a market capitalization of $8.31 billion, a P/E ratio of 142.78 and a beta of 1.97. The stock has a 50-day moving average of $27.08 and a 200 day moving average of $23.49. Exelixis, Inc. has a one year low of $10.04 and a one year high of $29.50.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $99.01 million during the quarter, compared to the consensus estimate of $85.27 million. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The firm’s quarterly revenue was up 173.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.15) earnings per share. On average, analysts forecast that Exelixis, Inc. will post $0.27 EPS for the current fiscal year.
WARNING: “Stelios Papadopoulos Sells 200,000 Shares of Exelixis, Inc. (EXEL) Stock” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://stocknewstimes.com/2017/09/20/stelios-papadopoulos-sells-200000-shares-of-exelixis-inc-exel-stock.html.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc raised its holdings in Exelixis by 1.3% in the first quarter. Legal & General Group Plc now owns 84,763 shares of the biotechnology company’s stock worth $1,834,000 after purchasing an additional 1,078 shares in the last quarter. Aperio Group LLC increased its holdings in shares of Exelixis by 2.7% during the second quarter. Aperio Group LLC now owns 58,345 shares of the biotechnology company’s stock valued at $1,437,000 after acquiring an additional 1,514 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Exelixis by 7.0% during the second quarter. Teacher Retirement System of Texas now owns 23,251 shares of the biotechnology company’s stock valued at $573,000 after acquiring an additional 1,517 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Exelixis by 14.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,751 shares of the biotechnology company’s stock valued at $320,000 after acquiring an additional 1,838 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its holdings in shares of Exelixis by 26.6% during the second quarter. Meeder Asset Management Inc. now owns 9,957 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 2,091 shares in the last quarter. Institutional investors and hedge funds own 79.20% of the company’s stock.
EXEL has been the subject of several research analyst reports. BidaskClub upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Cowen and Company reiterated an “outperform” rating on shares of Exelixis in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $28.00 price target for the company in a research note on Tuesday, July 4th. William Blair restated an “outperform” rating on shares of Exelixis in a research note on Thursday, July 27th. Finally, Stifel Nicolaus restated a “hold” rating and set a $26.00 price target on shares of Exelixis in a research note on Thursday, September 7th. Five investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $26.51.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.